Risperdal vs. Vraylar

See how Risperdal and Vraylar compare on approved uses, dosing, side effects, and cost.

Key Takeaways

  • Both drugs are atypical antipsychotics, but Risperdal is approved for schizophrenia, bipolar mania, and autism-related irritability, while Vraylar also covers bipolar depression and add-on therapy for major depressive disorder.

  • Risperdal has been available since 1993 and comes in a low-cost generic, while Vraylar has no generic version and typically costs several times more per month.

  • Vraylar has a long half-life, so dose changes take weeks to fully show their effect, while Risperdal reaches steady levels faster and comes in more formulations, including a liquid and a dissolving tablet.

Risperdal vs. Vraylar Drug Summary

Risperdal

Risperdal (risperidone) is an atypical antipsychotic available as a tablet, oral solution, or dissolving tablet, usually taken once or twice daily. It is FDA-approved for schizophrenia in adults and teens, manic or mixed episodes of bipolar I disorder, and irritability linked to autistic disorder in children. Dosing starts low and increases gradually to a typical maintenance range of 4 mg to 8 mg per day.

Vraylar

Vraylar (cariprazine) is an atypical antipsychotic capsule taken once daily, with or without food. It is FDA-approved for schizophrenia and bipolar I mania in adults, along with bipolar I depression and, as an add-on, major depressive disorder. Dosing starts low and rises slowly, since its long-acting metabolites take weeks to show their full effect.

Risperdal vs. Vraylar Side Effects

Risperdal

Most common
insomnia (up to 32%)
somnolence (up to 25%)
parkinsonism (up to 17%)
dizziness (up to 14%)

Vraylar

Most common
extrapyramidal symptoms (up to 19%)
akathisia (up to 13%)
somnolence (up to 7%)
dyspepsia (up to 5%)

Risperdal vs. Vraylar Dosage

Risperdal

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 2 mg once daily Day 1
Maximum dose 2 mg once daily Same as starting
Dose changes None Fixed dose

Vraylar

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 1.5 mg once daily Day 1
Maximum dose 1.5 mg to 6 mg daily Day 3 onward
Dose changes 2 increases Every day

Risperdal vs. Vraylar Indications

Risperdal

Risperdal is FDA-approved for schizophrenia in adults and teens 13 and older, for manic or mixed episodes of bipolar I disorder, and for irritability tied to autistic disorder in children and teens. Doctors also prescribe it off-label for tic disorders like Tourette syndrome and to boost antidepressants in treatment-resistant OCD.

  • Schizophrenia (ages 13 and up)

  • Bipolar I manic or mixed episodes

  • Irritability from autistic disorder

  • Off-label: OCD augmentation, tics

Vraylar

Vraylar is FDA-approved for schizophrenia and manic or mixed episodes of bipolar I disorder in adults, plus depressive episodes of bipolar I disorder. It is also approved as an add-on to antidepressants for major depressive disorder, and for bipolar mania in children as young as 10.

  • Schizophrenia (adults)

  • Bipolar I manic or mixed episodes

  • Bipolar I depression (adults)

  • Add-on for major depressive disorder

Risperdal vs. Vraylar Pros and Cons

Risperdal

Risperdal has been on the market since 1993, giving decades of real-world safety data, and it is available as a low-cost generic in multiple forms. Like all antipsychotics it carries a boxed warning against use in elderly dementia-related psychosis, and it carries a comparatively high risk of prolactin-related side effects.

Pros

  • Available as an inexpensive generic

  • Comes in tablet, liquid, and dissolving-tablet forms

  • Long track record dating back to 1993

Cons

  • Higher risk of prolactin elevation than many newer antipsychotics

  • Parkinsonism and dizziness are common during titration

  • Not approved for elderly dementia-related psychosis (boxed warning)

Vraylar

Vraylar covers a wider mood-disorder range, including bipolar depression and add-on therapy for major depressive disorder, uses Risperdal does not have. It has no generic version yet, so out-of-pocket costs are far higher, and its long half-life means side effects and benefits can take weeks to fully appear.

Pros

  • FDA-approved for bipolar depression and MDD add-on therapy

  • Once-daily capsule with a simple titration schedule

  • Metabolic changes in lipids and blood sugar trend milder in trials

Cons

  • No generic version; roughly $1,300 to $1,900 per month without insurance

  • Akathisia can affect up to 20% of patients during bipolar mania treatment

  • Long half-life delays full effect of dose changes by several weeks

Common Symptoms and Related Diseases You Can Explore

Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.